EAAT3 Inhibitor Compounds for Glutamate Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder, and autism spectrum disorder have limited efficacy and are associated with significant unmet medical needs, particularly due to the involvement of serotonin and glutamate abnormalities, where existing therapies do not adequately address the underlying pathophysiological elements.
Innovation Solution
Development of compounds that act as EAAT3 inhibitors, specifically targeting the excitatory amino acid transporter 3 (EAAT3), to modulate glutamate levels and signaling, thereby providing a novel therapeutic approach for these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional serotonergic therapies (SSRIs, TCAs) are used to treat psychiatric disorders, then some therapeutic benefit is achieved, but efficacy remains limited and unmet medical needs persist due to inadequate addressing of glutamate abnormalities
Solution Approach 1:
The patent transitions from serotonergic parameter modulation to glutamate transporter parameter modulation by developing EAAT3 inhibitor compounds. This parameter change targets a different neurochemical system (glutamate vs serotonin) and a different mechanism (transporter inhibition vs reuptake inhibition), thereby addressing the limitations of traditional therapies and expanding adaptability to underlying pathophysiological elements involving glutamate abnormalities.
2Adaptability or versatility
If EAAT3 inhibitor compounds are developed to target glutamate levels, then a novel therapeutic approach is provided, but device complexity and manufacturing challenges arise
Solution Approach 1:
The EAAT3 inhibitor compounds are designed with segmented molecular structures consisting of distinct functional groups (aromatic rings, amide linkages, heterocyclic moieties). This segmentation allows for modular synthesis, structure-activity relationship optimization, and systematic development of analogs, thereby managing complexity while maintaining novel therapeutic approach capability.
Solution Approach 2:
The patent employs parameter changes in molecular structure (substituent variations, stereochemistry, molecular weight, lipophilicity) to optimize the balance between novel therapeutic approach and manufacturability. By systematically varying structural parameters, the invention achieves effective EAAT3 inhibition while maintaining practical synthesis and production feasibility.
Data Source
AI summary
The present invention relates to compounds of formula I wherein R1' is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropyl-methyl or hydroxy- methyl; R3 is hydrogen, CI, F, CF3, CH3, isopropyl, methoxy, cyano or cyclopropyl; R4 is hydrogen, CH3, F or CI; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.